Dong-A Mulls Fresh Options After Allergan Ends Evogliptin Deal

With Allergan handing back the global development and sales rights of evogliptin as a NASH therapy to Dong-A, the South Korean firm is now considering an alternative business model around the DPP-4 inhibitor.

Liver anatomy

Allergan PLC has returned the global development and sales rights of evogliptin as a non-alcoholic steatohepatitis (NASH) therapy to Dong-A ST Co. Ltd. as of Nov. 1, ending a 2016 licensing agreement for the DPP-4 inhibitor.

[Sidebar#SC089424]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip